To determine if everolimus, a more potent mTOR inhibitor, would be tolerable and effective at augmenting the activity of hypomethylating agents in AML, we herein report a dose-finding study of azacitidine in combination with the rapamycin derivative everolimus in relapsed and refractory AML. Here, MTOR is linked to acute myeloid leukemia.